Latest News and Press Releases
Want to stay updated on the latest news?
-
Life-threatening allergies may be triggered by respiratory virus vaccines, such as influenza and COVID. Repeated doses may sensitize patients.
-
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pollen Allergy was valued...
-
Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report...
-
GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...
-
Allergy Conjunctivitis Global Market Report 2023: Rise in Air Pollutants and Chemicals Drives Growth
Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Allergy Conjunctivitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global allergy conjunctivitis market...
-
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...
-
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...
-
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
-
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
-
PRESS RELEASE AB SCIENCE TO PRESENT ON ITS AMYOTROPHIC LATERAL SCLEROSIS (ALS) DEVELOPMENT PROGRAM AT THE 2022 ALS DRUG DEVELOPMENT SUMMIT Paris, 07 February, 2022, 6pm CET AB Science SA (Euronext...